目的分析2015~2017年吉林省流行的柯萨奇病毒A组16型(coxasckievirus A16,CVA16)的流行特征、种系进化及基因特征。方法收集2015~2017年吉林省手足口病(hand,foot and mouth disease,HFMD)患儿的咽拭子或粪便标本,通过病毒分离筛选出CV...目的分析2015~2017年吉林省流行的柯萨奇病毒A组16型(coxasckievirus A16,CVA16)的流行特征、种系进化及基因特征。方法收集2015~2017年吉林省手足口病(hand,foot and mouth disease,HFMD)患儿的咽拭子或粪便标本,通过病毒分离筛选出CVA16阳性毒株,并对其VP1编码区基因组核苷酸序列进行测定和分析。结果24株CVA16流行株均为B1b基因亚型,与甘肃株核苷酸和氨基酸序列同源性分别为94.6%~96.1%和99.6%~100%;24株CVA16流行株氨基酸序列的第11、14、23、221及266位点发生了氨基酸突变。结论CVA16为吉林省HFMD的主要病原体之一,24株CVA16流行株与2007年甘肃株亲缘关系最近,与2008年青海株相比,共发生了5处氨基酸位点突变。展开更多
Background Hepatic arterial infusion chemotherapy for liver metastases is under evaluation because of the high target dose and low general toxicity. To investigate the efficacy and safety of a Folfox4 regimen administ...Background Hepatic arterial infusion chemotherapy for liver metastases is under evaluation because of the high target dose and low general toxicity. To investigate the efficacy and safety of a Folfox4 regimen administered through a combined hepatic arterial and systemic infusion for the first-line treatment of colorectal cancer （CRC） with unresectable liver metastases. Methods Twenty-seven CRC patients with unresectable hepatic metastases and no prior chemotherapy were enrolled into the study. They received a Folfox4 regimen; 1st day： HAl of oxaliplatin 85 mg/m2 and L-folinic acid 200 mg/m2, followed by a bolus hepatic arterial injection of 5-fluorouracil 400 mg/m2, then continuous HAl of 5-FU 600 mg/m2; 2nd day： infusion of L-folinic acid 200 mg/m2 i.v. followed by an intravenous bolus injection of 5-Fluorouraci1400 mg/m2, then continuous infusion of 5-fluorouracil 600 mg/m2 i.v. The patients received HAl during the odd cycles, and the intravenous administration of the same Folfox4 regimen during the even cycles. Results A total of 236 treatment cycles were given with a median of 10 cycles. The therapy generated the following results after six treatment cycles： complete response （CR） 1/27 （3.7%）, partial response （PR） 17/27 （63.0%）, stable disease （SD） 6/27 （22.2%）, and progress disease （PD） 3/27 （11.1%）. Five patients had hepatectomy. The serum levels of both carcinoembryonic antigen （CEA） and CA19-9 were significantly reduced （P〈0.05）. A median time to progression of 11 months and a median overall survival of 24 months were documented. The major adverse events included grade 1/2 nausea/vomiting, upper abdominal pain, peripheral neuropathy, and neutropenia/thrombocytopenia. Conclusions The Folfox4 regimen administered through combined hepatic arterial and systemic infusions is efficacious and safe for the treatment of CRC with unresectable liver metastases, and it facilitates the control of local lesions.展开更多
文摘目的分析2015~2017年吉林省流行的柯萨奇病毒A组16型(coxasckievirus A16,CVA16)的流行特征、种系进化及基因特征。方法收集2015~2017年吉林省手足口病(hand,foot and mouth disease,HFMD)患儿的咽拭子或粪便标本,通过病毒分离筛选出CVA16阳性毒株,并对其VP1编码区基因组核苷酸序列进行测定和分析。结果24株CVA16流行株均为B1b基因亚型,与甘肃株核苷酸和氨基酸序列同源性分别为94.6%~96.1%和99.6%~100%;24株CVA16流行株氨基酸序列的第11、14、23、221及266位点发生了氨基酸突变。结论CVA16为吉林省HFMD的主要病原体之一,24株CVA16流行株与2007年甘肃株亲缘关系最近,与2008年青海株相比,共发生了5处氨基酸位点突变。
文摘Background Hepatic arterial infusion chemotherapy for liver metastases is under evaluation because of the high target dose and low general toxicity. To investigate the efficacy and safety of a Folfox4 regimen administered through a combined hepatic arterial and systemic infusion for the first-line treatment of colorectal cancer （CRC） with unresectable liver metastases. Methods Twenty-seven CRC patients with unresectable hepatic metastases and no prior chemotherapy were enrolled into the study. They received a Folfox4 regimen; 1st day： HAl of oxaliplatin 85 mg/m2 and L-folinic acid 200 mg/m2, followed by a bolus hepatic arterial injection of 5-fluorouracil 400 mg/m2, then continuous HAl of 5-FU 600 mg/m2; 2nd day： infusion of L-folinic acid 200 mg/m2 i.v. followed by an intravenous bolus injection of 5-Fluorouraci1400 mg/m2, then continuous infusion of 5-fluorouracil 600 mg/m2 i.v. The patients received HAl during the odd cycles, and the intravenous administration of the same Folfox4 regimen during the even cycles. Results A total of 236 treatment cycles were given with a median of 10 cycles. The therapy generated the following results after six treatment cycles： complete response （CR） 1/27 （3.7%）, partial response （PR） 17/27 （63.0%）, stable disease （SD） 6/27 （22.2%）, and progress disease （PD） 3/27 （11.1%）. Five patients had hepatectomy. The serum levels of both carcinoembryonic antigen （CEA） and CA19-9 were significantly reduced （P〈0.05）. A median time to progression of 11 months and a median overall survival of 24 months were documented. The major adverse events included grade 1/2 nausea/vomiting, upper abdominal pain, peripheral neuropathy, and neutropenia/thrombocytopenia. Conclusions The Folfox4 regimen administered through combined hepatic arterial and systemic infusions is efficacious and safe for the treatment of CRC with unresectable liver metastases, and it facilitates the control of local lesions.
